Serina Therapeutics COO Tacey Viegas to retire July 15; consulting agreement extends stock options

Serina Therapeutics, Inc.

Tacey Viegas notified retirement as COO effective July 15, 2024.
Separation agreement provides 12 months of base salary plus $1,000/month.
Consulting agreement extends options on 341,889 shares at $0.06 per share.
No other compensation under consulting agreement beyond option extension.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Tacey Viegas

Chief Operating Officer

SER · Serina Therapeutics, Inc.

Effective: 2024-07-15
Filed: July 12, 2024, 7:59 PM ET

On July 9, 2024, Tacey Viegas, Chief Operating Officer of Serina Therapeutics, Inc. (the “ Company ”), notified the Company that he will retire effective July 15, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tacey Viegas departed as Chief Operating Officer at Serina Therapeutics, Inc..

Action: retire
Role: Chief Operating Officer

Exact text from the filing

On July 9, 2024, Tacey Viegas, Chief Operating Officer of Serina Therapeutics, Inc. (the “ Company ”), notified the Company that he will retire effective July 15, 2024

View on SEC.gov

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-027113

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.